Key Points
- Insider Chad Cowan purchased 58,060 shares on Dec. 22 at $0.85 each, increasing his holding to 1,045,087 shares—a 5.88% boost—worth about $888,324.
- Shares traded down ~7.8% (opened $1.00) and the company posts negative EPS (recent quarter ($0.32)); Century Therapeutics has a market cap of ~$87.4M, a 12‑month range of $0.34–$1.19, and an average analyst rating of Hold with a $3.40 consensus target.
- Multiple institutional investors (e.g., Two Sigma, Citadel, GSA) have recently increased positions, and institutions now own about 50.2% of the stock.
Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) insider Chad Cowan bought 58,060 shares of Century Therapeutics stock in a transaction on Monday, December 22nd. The stock was acquired at an average price of $0.85 per share, for a total transaction of $49,351.00. Following the transaction, the insider directly owned 1,045,087 shares of the company's stock, valued at approximately $888,323.95. This trade represents a 5.88% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Century Therapeutics Trading Down 7.8%
NASDAQ IPSC opened at $1.00 on Tuesday. The stock has a fifty day simple moving average of $0.62 and a 200-day simple moving average of $0.57. The stock has a market cap of $87.40 million, a PE ratio of -3.13 and a beta of 1.80. Century Therapeutics, Inc. has a twelve month low of $0.34 and a twelve month high of $1.19.
Century Therapeutics (NASDAQ:IPSC - Get Free Report) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.07. Century Therapeutics had a negative net margin of 19.10% and a negative return on equity of 10.01%. Research analysts predict that Century Therapeutics, Inc. will post -1.61 EPS for the current year.
Institutional Trading of Century Therapeutics
Large investors have recently modified their holdings of the stock. Two Sigma Investments LP raised its stake in shares of Century Therapeutics by 59.2% in the third quarter. Two Sigma Investments LP now owns 911,446 shares of the company's stock valued at $454,000 after acquiring an additional 338,902 shares in the last quarter. GSA Capital Partners LLP increased its holdings in Century Therapeutics by 29.3% during the 3rd quarter. GSA Capital Partners LLP now owns 603,479 shares of the company's stock worth $301,000 after purchasing an additional 136,873 shares during the period. Jane Street Group LLC acquired a new stake in Century Therapeutics in the 2nd quarter valued at about $248,000. Citadel Advisors LLC raised its position in Century Therapeutics by 64.1% in the 3rd quarter. Citadel Advisors LLC now owns 360,825 shares of the company's stock valued at $180,000 after purchasing an additional 140,891 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its stake in shares of Century Therapeutics by 101.2% in the 1st quarter. Acadian Asset Management LLC now owns 284,229 shares of the company's stock valued at $133,000 after buying an additional 142,953 shares during the period. Hedge funds and other institutional investors own 50.20% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities analysts recently weighed in on the stock. Leerink Partnrs cut shares of Century Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday, November 17th. Wall Street Zen lowered Century Therapeutics from a "hold" rating to a "sell" rating in a research report on Monday, October 20th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Century Therapeutics in a research note on Wednesday, October 8th. Finally, Leerink Partners reissued a "market perform" rating and set a $2.00 target price (down previously from $7.00) on shares of Century Therapeutics in a research note on Monday, November 17th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $3.40.
Check Out Our Latest Stock Report on IPSC
About Century Therapeutics
(
Get Free Report)
Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.
The company's proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
